Cloning Substrate Post-Dolly (1996-2026)

30-year industrial continuation of mammalian somatic cell nuclear transfer (SCNT) since Dolly (Roslin 1996). The announcement layer — shaped by the 2005 Hwang Woo-suk fraud, the iPSC institutional pivot, and the He Jiankui scandal — treats cloning as a dead 1990s science. The substrate layer is a continuous commercial bio-foundry pipeline: Sooam (1,000+ dogs since 2006), ViaGen (600 dogs + 400 cats by 2024), Sinogene (500+ pet clones + 1,000-beagle surrogate base since 2017), Trans Ova (2,000+ livestock clones, FDA-cleared since 2008), plus CAS Shanghai's primate SCNT monopoly (Zhong Zhong/Hua Hua 2018, Retro 2024) and Colossal Biosciences' EPC-SCNT + multiplex-CRISPR de-extinction pipeline (dire wolf 2025/2026 — see kayfabe correction). Substrate-vs-Announcement Layer Divergence canonical 30-year instance. Apex Superposition: (a) coordinated regulatory-bypass + (b) Turchin SDT capital-flight to least-resistance jurisdictions + (c) compound-null commercial scaling + (d) intelligence-capital dual-use boundary all load-bearing — held simultaneously. Cross-substrate forward-reference (Reports #90 + cross-arc backfill): The 30-year SCNT post-Dolly architecture (1996-2026) closes into the MAHA biological-substrate state-policy deployment arc identified in Report #90 — the April 18 2026 Trump Psychedelic Executive Order ($50M ARPA-H ibogaine + FDA Right-to-Try Schedule I expansion) operates the same regulatory-bypass architecture under the same HHS Secretary (RFK Jr.) and the same FDA Plausible Mechanism Framework (Feb 23 2026) that this cloning substrate established. Cloning-pharmaceutical (SCNT/iPSC/Colossal/ATAI-portfolio-bio-companies) and psychedelic-pharmaceutical (ATAI/Compass/MAPS-displaced) operate as parallel biological-substrate capital deployments under the unified MAHA administrative architecture. Report #181: two documented extensions — (1) Hanna lab (Weizmann) stem-cell-based embryo models: human pluripotent cells reverted to a naive state and self-organized into complete 14-day embryo-like structures with placenta, yolk sac and chorionic sac, no gametes and no womb, architectural parity checked against classical embryology atlases. (2) ISSCR 2025 targeted guideline update SPECIFICALLY for embryo models [live-verified: Jun 2025, Clark/Rossant-led; all other sections remain 2021] — governance actively redrawing categories to manage synthetic embryonic entities. SYNTHESIS-CANDIDATE (parked, adversarial gate): the naive-state requirement — strip cells to an undifferentiated 'blank' before imposing new form — is structurally consistent with the alchemical materia-prima/putrefaction move; resemblance noted, nothing wired. Report #183 — adjacent chassis added at tier: INTERSPECIES CHIMERAS (mouse pancreas grown in Pdx1-null rats normalised diabetic mice >370 days without immunosuppression, Nature 2017; human epiblast contribution in 132 macaque blastocysts peaked at 7.08% at day 15, Cell 2021; humanised pig mesonephros to embryonic day 28, 2023; xenophagocytosis identified as the clearance mechanism limiting human chimerism, Cell 2026) — the living animal as bioreactor with a genetic empty niche as the specification. XENOTRANSPLANTATION: the only place an engineered non-human organ is currently sustaining a human — 10-edit pig heart (NEJM 2022, death day 60), 69-edit pig kidney into a living recipient (Mar 2024), first pig liver (Nature 2025); every publicised graft has failed or been removed. DE-EXTINCTION as the field's cleanest claim-outruns-genetics case: Colossal's woolly mouse is an unrefereed preprint, the 'dire wolves' shipped with no methodology paper, and the IUCN SSC Canid Specialist Group states flatly 'the three animals produced by Colossal are not dire wolves. Nor are they proxies of the dire wolf.'